Noventure, S. L. (Spain)

Noventure, S. L. is a Spanish healthcare company headquartered in Barcelona. It describes itself as the home of a portfolio of clinically proven, consumer-focused healthcare brands, with a mission to build trust worldwide by providing clinically backed products that offer real relief without harm. Rather than operating as a single-product manufacturer, Noventure positions itself as a brand house: it develops, owns and commercialises a set of therapeutic consumer brands, each aimed at a specific, well-defined medical need. The company's brand portfolio includes Tasectan, a treatment for acute diarrhoea; Utipro Plus AF, for the control and prevention of urinary tract infections (UTIs); and Ulkox, for the healing of anal fissures. These are positioned as consumer-friendly but clinically serious products, sitting at the intersection of over-the-counter self-care and evidence-based medicine. Noventure states that every product is backed by clinical trials, that its brands are included in treatment guidelines across Europe and beyond, that all products are CE-marked and fully compliant with MDR Class III requirements, and that they are protected by patents. Geographically, Noventure states that its brands are trusted in over 50 countries, and it expresses the ambition of making them the number one choice worldwide in their respective therapeutic classes. Its commercial model therefore combines local market access and distribution with centrally held clinical dossiers, regulatory compliance and intellectual property. The company maintains an active communications programme around clinical evidence, including participation in specialist congresses such as ESPGHAN and publications on product performance. Noventure is a private company. Public information about its ownership structure, founding year and executive team is limited; the company is primarily documented through its own corporate website and a Wikidata entry identifying it as a company in Barcelona, Spain. Its identity is that of a specialty healthcare brand owner and marketer rather than a listed pharmaceutical group.

Noventure, S. L. is a Spanish healthcare company based in Barcelona. It has built its business around a portfolio of clinically proven, consumer-focused healthcare brands rather than around a single flagship medicine. The company's public narrative emphasises clinical evidence, regulatory compliance and intellectual property as the foundations of its brands. From the outset, Noventure has positioned its products at the boundary between self-care and prescription-grade evidence. Its brands are described as backed by clinical trials, included in treatment guidelines across Europe and beyond, CE-marked and fully compliant with MDR Class III requirements, and protected by patents. This combination is presented as the company's core differentiator in the consumer healthcare space. The portfolio has been developed around specific therapeutic needs. Tasectan addresses acute diarrhoea; Utipro Plus AF targets the control and prevention of urinary tract infections; and Ulkox is indicated for the healing of anal fissures. These brands are marketed directly to consumers and healthcare professionals, with clinical dossiers made available to support their use. International expansion is central to Noventure's strategy. The company states that its brands are trusted in over 50 countries and that its mission is to make them the number one choice worldwide in their therapeutic class. This implies a model based on local distribution and market access partners combined with centrally managed clinical, regulatory and IP assets. Noventure also maintains an active scientific communication programme. Its website highlights participation in specialist congresses such as ESPGHAN, held in Lille, and publications on product performance, including results with EHO-85. It also notes the inclusion of Tasectan and Xilaplus in new German treatment guidelines. These activities are used to reinforce the clinical credibility of the portfolio. Publicly available information about Noventure's corporate history is limited. It is identified as a company in Barcelona, Spain, and is a private entity. Details such as its exact founding year, ownership structure and executive leadership are not disclosed in the sources available. Its documented identity is that of a specialty healthcare brand owner and marketer operating across multiple international markets.

• Tasectan and Xilaplus included in new German treatment guidelines.

• New publication reporting good results with EHO-85.

• Noventure participates in ESPGHAN congress in Lille.

Clinically backed, IP-protected consumer healthcare brands included in treatment guidelines and trusted in over 50 countries.

• Tasectan

  Treatment for acute diarrhoea.

• Utipro Plus AF

  Control and prevention of urinary tract infections (UTIs).

• Ulkox

  Healing of anal fissures.

• Xilaplus

  Brand mentioned in connection with new German treatment guidelines.

• EHO-85

  Product referenced in a publication reporting good results.

1. 1Noventure official website homepagenoventure.com
2. 2About Us – Noventurenoventure.com
3. 3Noventure, S. L. (Spain) – Wikidatawikidata.org